Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD). The award of $150,000 will support the Company’s ongoing efforts to develop its NSI-566 human neural stem cell line as a candidate therapeutic for severe Traumatic Brain Injury (TBI).
{iframe}https://globenewswire.com/news-release/2018/06/11/1519489/0/en/Neuralstem-Awarded-Phase-I-SBIR-Contract-to-Support-Research-into-Neural-Stem-Cell-Therapy-for-Severe-Traumatic-Brain-Injury.html{/iframe}